Analysts are offering conflicting projections for Pfizer Inc. stock prices over the next three years as the company navigates a portfolio transition.
This divergence in outlook reflects a critical turning point for the pharmaceutical giant. The company must replace revenue from aging blockbuster drugs with new successful product launches to maintain its market position.
Some market observers view the current period as a painful recovery. Seeking Alpha said that positive data for multiple pipeline candidates highlight progress and make the stock a buy [3]. These growth drivers include advancements in the company's vaccine and oncology sectors.
Oncology is already a significant pillar of the business, contributing roughly 27% [4] of total revenues. The company is leaning on these specialized treatments to offset losses elsewhere.
However, other analysts warn of significant risks. Yahoo Finance said that Pfizer's major blockbusters have been on the decline, creating a major turning point and risk for the stock [1]. This decline puts pressure on the company to accelerate the development of its next generation of medicines.
Competitive positioning also remains a concern. Reports from The Globe and Mail said there is a continuing battle in the big pharma sector, specifically comparing Pfizer's trajectory against competitors like AbbVie [4].
The uncertainty surrounding the 2027 price target stems from whether the pipeline can scale quickly enough to fill the revenue gap. While the oncology data is promising, the overall stock performance depends on the commercial success of these new candidates in the U.S. market [2].
“Oncology contributes roughly 27% of Pfizer's total revenues.”
Pfizer is currently in a high-stakes transition period where its future valuation depends on shifting from pandemic-era windfalls to a sustainable, diversified portfolio. The tension between declining legacy drug sales and promising oncology data creates a volatility window for investors through 2027.
